Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Genomic Alterations”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06772623
What this trial is testing

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Who this might be right for
Non Small Cell Lung Carcinoma
AbbVie 252
Large-scale testing (Phase 3)Looking for participantsNCT05768178
What this trial is testing

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Who this might be right for
Haematological MalignancyMelanomaThyroid Cancer, Papillary+9 more
Cancer Research UK 30
Not applicableWithdrawnNCT00298064
What this trial is testing

Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer

Who this might be right for
Cervical CancerCervix
University of New Mexico
Large-scale testing (Phase 3)Active Not RecruitingNCT05215340
What this trial is testing

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

Who this might be right for
Metastatic Non Small Cell Lung Cancer
Daiichi Sankyo 740
Not applicableLooking for participantsNCT05406232
What this trial is testing

Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer

Who this might be right for
Breast CarcinomaInvasive Breast Carcinoma
M.D. Anderson Cancer Center 36
Not applicableStudy completedNCT01284010
What this trial is testing

Biomarkers in Blood and Bone Marrow Samples From Patients With Acute Lymphoblastic Leukemia

Who this might be right for
Leukemia
Alliance for Clinical Trials in Oncology 200
Not applicableUnknownNCT04125446
What this trial is testing

Genomic and Epigenomic Alterations After Cancer Treatment in Pregnancy

Who this might be right for
CancerPregnancy
University Hospital, Gasthuisberg 150
Not applicableUnknownNCT05707585
What this trial is testing

Lung Cancer Diagnosis by Detecting Epigenetic Imprinting Alterations in Bronchoalveolar Lavage

Who this might be right for
Lung Cancer
The Second Affiliated Hospital of Dalian Medical University 2,064
Not applicableUnknownNCT06234579
What this trial is testing

Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)

Who this might be right for
ALK Gene MutationNSCLC Stage IVALK Sensitizing Mutation
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 108
Testing effectiveness (Phase 2)Active Not RecruitingNCT06644768
What this trial is testing

Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

Who this might be right for
Non-small Cell Lung CancerLung Cancer
Daiichi Sankyo 137
Testing effectiveness (Phase 2)Study completedNCT04173507
What this trial is testing

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

Who this might be right for
Advanced Lung Non-Squamous Non-Small Cell CarcinomaRecurrent Lung Non-Squamous Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8+2 more
SWOG Cancer Research Network 47
Early research (Phase 1)Ended earlyNCT02228811
What this trial is testing

DCC-2701 in Participants With Advanced Solid Tumors

Who this might be right for
Locally Advanced TumorsMetastatic Solid TumorsCancers With MET Genomic Alterations+1 more
Deciphera Pharmaceuticals, LLC 44
Not applicableLooking for participantsNCT05296421
What this trial is testing

Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer

Who this might be right for
Pancreatic Ductal Adenocarcinoma
Rutgers, The State University of New Jersey 16
Not applicableLooking for participantsNCT07649629
What this trial is testing

Impact of Liquid Biopsy on the Therapeutic Pathway for Lung Cancer: Advancing the Molecular Characterization of Patients With Advanced Lung Adenocarcinoma by Integrating Liquid Biopsy Into the Early Stages of the Diagnostic and Therapeutic Pathway

Who this might be right for
Advanced Non-small Cell Lung Cancer (NSCLC)
Regina Elena Cancer Institute 70
Not applicableLooking for participantsNCT06659926
What this trial is testing

The Radium-select Study

Who this might be right for
mCRPCMale Urogenital Diseases
The Netherlands Cancer Institute 60
Not applicableUnknownNCT00166738
What this trial is testing

Analysis of Genomic DNA Alterations in Familial Schizophrenia

Who this might be right for
Schizophrenia
National Taiwan University Hospital 20
Large-scale testing (Phase 3)Not Yet RecruitingNCT07672223
What this trial is testing

SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd. 570
Testing effectiveness (Phase 2)Active Not RecruitingNCT02365597
What this trial is testing

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Who this might be right for
Urothelial Cancer
Janssen Research & Development, LLC 239
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07158840
What this trial is testing

AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment

Who this might be right for
Non-Small Cell Lung Cancer
Akeso 60
Not applicableStudy completedNCT01164735
What this trial is testing

Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Who this might be right for
Recurrent Uterine Corpus CarcinomaStage III Uterine Corpus CancerStage IV Uterine Corpus Cancer
Gynecologic Oncology Group 169
Next Page